@Article{096504017X15051752095738,
AUTHOR = {Xinyang Liu, Zhichao Wang, Zongwei Chen, Longzi Liu, Lijie Ma, Liangqing Dong, Zhao Zhang, Shu Zhang, Liuxiao Yang, Jieyi Shi, Jia Fan, Xiaoying Wang, Qiang Gao},
TITLE = {Efficacy and Safety of Transcatheter Arterial Chemoembolization and  Transcatheter Arterial Chemotherapy Infusion in Hepatocellular Carcinoma:  A Systematic Review and Meta-Analysis},
JOURNAL = {Oncology Research},
VOLUME = {26},
YEAR = {2018},
NUMBER = {2},
PAGES = {231--239},
URL = {http://www.techscience.com/or/v26n2/56634},
ISSN = {1555-3906},
ABSTRACT = {Hepatocellular carcinoma (HCC) is a worldwide health threat with increasing incidence and a high mortality rate. Most HCC patients are diagnosed at an advanced stage and are unable to undergo potential curative 
surgery. Transcatheter arterial chemoembolization (TACE) and transcatheter arterial chemotherapy infusion 
(TACI) are two of the main palliative treatments for advanced HCC patients. The clinical efficacy and safety 
of TACE and TACI are controversial. For this reason, we conducted a systematic review and meta-analysis to 
summarize the current evidence. We searched for randomized controlled trials (RCTs) and cohort studies that 
compared the clinical outcomes and adverse effects in HCC patients who received TACE or TACI treatments. 
The database search was performed and last updated on November 1, 2016. Overall survival and clinical 
response were compared using a hazard ratio (HR) with a 95% confidence interval (CI). A total of 11 clinical 
studies that included 13,090 patients were included based on the inclusion/exclusion criteria, of which 9 were 
cohort studies and 2 were RCTs. TACE was associated with a 23% lower hazard of death compared to TACI 
(pooled HR = 0.77, 95% CI = 0.67–0.88, <i>p</i> = 0.0002). Patients receiving TACE had a 28% higher disease control 
rate (DCR) and 162% higher objective response rate (ORR). Only the increase in ORR associated with TACE 
was statistically significant [DCR: odds ratio (OR) = 1.28, 95% CI = 0.35–4.64, <i>p</i> = 0.71; ORR: OR = 2.62, 95% 
CI = 1.33–5.15, <i>p</i> = 0.002]. TACE is associated with more favorable survival and response rate than TACI in 
patients with intermediate or advanced HCC.},
DOI = {10.3727/096504017X15051752095738}
}